Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?-Reference-Cited by-同舟云学术

Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?

Published:2024-03-06 Issue:10 Volume:31 Page:1224-1226
ISSN:2047-4873
Container-title:European Journal of Preventive Cardiology
language:en
Short-container-title:

Author:

Watts Gerald F¹²,Chan Dick C¹

Affiliation:

1. Medical School, Faculty of Health and Medical Sciences, University of Western Australia , GPO Box X2213, Perth, Western Australia 6847 , Australia

2. Lipid Disorders Clinic, Department of Cardiology and Internal Medicine, Royal Perth Hospital , 197 Wellington Street, Perth, Western Australia 6000 , Australia

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwae095/56975380/zwae095.pdf

Reference23 articles.

1. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society;Ginsberg;Eur Heart J,2021

2. 2021 ACC Expert Consensus Decision Pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia;Virani;J Am Coll Cardiol,2021

3. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study;Björnson;Eur Heart J,2023

4. Angiopoietin-like 3: an important protein in regulating lipoprotein levels;Burks;Best Pract Res Clin Endocrinol Metab,2023

5. Angiopoietin-like 3 (ANGPTL3) and atherosclerosis: lipid and non-lipid related effects;Lupo;J Cardiovasc Dev Dis,2018